Indolent B-Cell Non-Hodgkin Lymphoma — Trials

Indolent B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 172
Recruiting: 85
Ph III recruiting: 4
Growth YoY: +34.6%
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06513234	Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas	recruiting	Phase 2	45	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Jul 22, 2024	clinicaltrials
NCT06454968	Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.	recruiting	Phase 2	45	Peking Union Medical College HospitalOTHER	1	Jun 18, 2024